bioAffinity Technologies, Inc. 8K

bioAffinity Technologies reported Q2 2026 financial results showing strong growth in CyPath Lung test volume and revenue, ongoing operating losses, pipeline and clinical trial progress, patent advancement, and completion of a $3.2 million public offering.

bioAffinity Technologies, Inc. filed a Form 8-K to furnish its second quarter 2026 financial results and operational update, reporting that revenue for the quarter ended June 30, 2026 increased 19% year over year to $1.5 million driven primarily by strong growth in its CyPath Lung diagnostic test, including a 216% increase in test volume, a 159% increase in CyPath Lung testing revenue for the first six months of 2026, and a significant expansion in physician adoption and test reports delivered, while the company continued to incur operating losses, advanced a large longitudinal clinical trial supported by the John P. Murtha Cancer Center Research Program, progressed development of precision diagnostics for asthma and COPD and topical siRNA-based skin cancer therapeutics, received allowance of a key Mexican patent, and completed a June 2026 public offering raising approximately $3.2 million in gross proceeds to support commercialization, clinical development, and general corporate purposes.

Filing Facts

CIK

1712762

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-036486

Alert Tier

7